Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EBIT (2020 - 2026)

Maxcyte has reported EBIT over the past 6 years, most recently at $31.3 million for Q4 2025.

  • Quarterly EBIT rose 5.34% to $31.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.4 million through Dec 2025, down 9.19% year-over-year, with the annual reading at -$9.4 million for FY2025, 9.19% down from the prior year.
  • EBIT was $31.3 million for Q4 2025 at Maxcyte, up from -$14.1 million in the prior quarter.
  • Over five years, EBIT peaked at $32.2 million in Q4 2023 and troughed at -$14.2 million in Q2 2025.
  • The 5-year median for EBIT is -$8.2 million (2022), against an average of -$2.9 million.
  • The largest YoY upside for EBIT was 577.57% in 2023 against a maximum downside of 216.85% in 2023.
  • A 5-year view of EBIT shows it stood at $9.2 million in 2021, then crashed by 173.17% to -$6.8 million in 2022, then skyrocketed by 577.57% to $32.2 million in 2023, then fell by 7.84% to $29.7 million in 2024, then increased by 5.34% to $31.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EBIT are $31.3 million (Q4 2025), -$14.1 million (Q3 2025), and -$14.2 million (Q2 2025).